OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - BOERSE MUENCHEN 01:05:07 06/07/2024 am IST | ||
| 9.7 EUR | +2.11% |
|
| Current month | -2.32% | ||
| 1 month | +2.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 9.7 | +2.11% |
| 04/24/04 | 9.5 | +4.97% |
| 03/24/03 | 9.05 | -8.22% |
| 02/24/02 | 9.86 | -5.10% |
| 01/24/01 | 10.39 | +4.63% |
Real-time BOERSE MUENCHEN
Last update July 06, 2024 at 01:05 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | HS1640 |
| ISIN | DE000HS16406 |
| Date issued | 11/08/2023 |
| Strike | 90.5 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.7 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.88 € |
|---|---|
| Lowest since issue | 0.62 € |
| Spread | 0.06 € |
| Spread % | 0.62% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Certificates
- Certificat
